Edwards Lifesciences Corporation (EW) News
Filter EW News Items
EW News Results
|Loading, please wait...|
EW News Highlights
- 500 - Internal server error
- Over the past 26 days, the trend for EW's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about EW are IQ, LI and LU.
Latest EW News From Around the Web
Below are the latest news stories about Edwards Lifesciences Corp that investors may wish to consider to help them evaluate EW as an investment opportunity.
Can You Imagine How Jubilant Edwards Lifesciences' (NYSE:EW) Shareholders Feel About Its 183% Share Price Gain?
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
IRVINE, Calif., June 1, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug…
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Real-world data shows that patients with bicuspid aortic stenosis treated with Edwards Lifesciences' (EW) SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement ("TAVR") had low risk of death and stroke one year following surgery.There were not significant differences in primary outcomes between bicuspid aortic patients and those with tricuspid aortic valve disease.A...
Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and at low risk of death from surgery. The data show excellent outcomes at one year, with low rates of death and stroke, and no significant differences in the primary outcomes compared with the overall cohort, or those with tricuspid aortic valve disease.
Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company's transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Edwards Lifesciences said its sees transcatheter aortic valve replacement (TAVR) sales rising as high as 20% this year.